A Phase 1/2 Open-label Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214 Nivolumab and Ipilimumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
The purpose of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of the study drug (NKTR-214) given together with Opdivo?.
The purpose of this study is to study the safety, tolerability, and effectiveness of the study drug (NKTR-214) given together with Opdivo.
- IRB Number: 1705311414 (NKTR16-214-02)
- Research Study Identifier: TX7957
- Principal Investigator: Roberto Pili, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required